氧托溴铵对哮喘患者中神经激肽A诱导的支气管收缩的影响。

The effect of oxitropium bromide on neurokinin A-induced bronchoconstriction in asthmatic subjects.

作者信息

Joos G, Pauwels R, Van Der Straeten M

机构信息

University Hospital, Department of Respiratory Diseases, Ghent, Belgium.

出版信息

Pulm Pharmacol. 1988;1(1):41-5. doi: 10.1016/0952-0600(88)90009-9.

DOI:10.1016/0952-0600(88)90009-9

PMID:2856543

Abstract

In some animal species substance P and neurokinin A (NKA) cause bronchoconstriction by the release of acetylcholine from postganglionic cholinergic nerve endings. The aim of the present study was to investigate the effect of an anticholinergic drug, oxitropium bromide, on bronchoprovocation with NKA in asthmatics. Eleven mild asthmatics (mean % predicted FEV1 85.5) received on 2 separate days, double blind, in a randomised order, 400 mcg oxitropium bromide or placebo, 90 min before challenge with NKA. NKA was inhaled at 3 concentrations (10(-4), 3.10(-4) and 10(-3) M). Specific airways conductance (sGaw) and forced expiratory volume in 1 s (FEV1) were used as parameters of airway calibre. Compared to the placebo-aerosol, oxitropium bromide caused a significant increase in sGaw and FEV1. On the placebo-treatment day, NKA caused a concentration-dependent decrease in sGaw and FEV1. The percentage changes in sGaw and FEV1 on the oxitropium day were not statistically different from those occurring on the placebo day. We conclude that oxitropium bromide caused a significant bronchodilation but offered no significant protection against NKA-induced bronchoconstriction in mild asthmatic subjects.

摘要

在一些动物物种中，P物质和神经激肽A（NKA）通过从节后胆碱能神经末梢释放乙酰胆碱而导致支气管收缩。本研究的目的是调查抗胆碱能药物氧托溴铵对哮喘患者吸入NKA后支气管激发试验的影响。11名轻度哮喘患者（预计FEV1平均百分比为85.5）在2个不同的日子，以双盲、随机顺序，在吸入NKA前90分钟接受400微克氧托溴铵或安慰剂。以3种浓度（10⁻⁴、3×10⁻⁴和10⁻³M）吸入NKA。比气道传导率（sGaw）和第1秒用力呼气容积（FEV1）用作气道口径的参数。与安慰剂气雾剂相比，氧托溴铵使sGaw和FEV1显著增加。在安慰剂治疗日，NKA使sGaw和FEV1呈浓度依赖性降低。氧托溴铵日sGaw和FEV1的百分比变化与安慰剂日相比无统计学差异。我们得出结论，氧托溴铵可引起显著的支气管舒张，但对轻度哮喘患者的NKA诱导的支气管收缩无显著保护作用。